Results from treating PCa mouse models with these vaccines showed that the group treated with MVA-BN-PSA-C1C2 exhibited increased immunogenicity against PSA compared to the control group, and it improved the efficacy of anti-tumor therapy [161]. The gene discussed is KLK3; the disease is posterior cortical atrophy.